Evidence map›Paper›PMID 40950489›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Impact of Medicaid Expansion on Lung Cancer Survival Outcomes: A Difference-in-Differences Analysis.

Oluwasegun Akinyemi, Mojisola Fasokun, Akachukwu Eze, Nkemdirim Ugochukwu, Sumaiyya Arshad, Orimisan Belie, Kakra Hughes, Edward Cornwell, Gal Levy

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Oluwasegun AkinyemiThe Clive O Callender Outcomes Research Center, Howard University College of Medicine, Washington DC, USA.
Mojisola FasokunDepartment of Epidemiology, University of Alabama at Birmingham, AL, USA.
Akachukwu EzeThe Clive O Callender Outcomes Research Center, Howard University College of Medicine, Washington DC, USA.ORCID 0009-0004-7521-2224
Nkemdirim UgochukwuThe Clive O Callender Outcomes Research Center, Howard University College of Medicine, Washington DC, USA.
Sumaiyya ArshadDepartment of Surgery, Howard University College of Medicine, Washington DC, USA.
Orimisan BelieDepartment of Tumor Biology, George Washington University, Washington DC, USA.
Kakra HughesDepartment of Surgery, Howard University College of Medicine, Washington DC, USA.
Edward CornwellDepartment of Surgery, Howard University College of Medicine, Washington DC, USA.
Gal LevyDepartment of Surgery, Howard University College of Medicine, Washington DC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe Affordable Care Act's Medicaid expansion aimed to enhance healthcare access for low-income individuals and minority groups, promoting early screening and treatment to improve health equity.

objectiveThis study examines the impact of Medicaid expansion on lung cancer-specific survival (CSM) and overall mortality (OS) by comparing outcomes in Texas (non-expansion of ACA) and California (expansion of ACA). METHODOLOGY: We conducted a retrospective study using data from SEER cancer registry (2007-2021) to evaluate the impact of Medicaid expansion on lung cancer survival in California (expansion) vs. Texas (non-expansion). The study included adults aged 18-64, with periods split into pre-ACA (2007-2013), one-year washout (2014), and post-ACA (2015-2021). We utilized a DID design and adjusted for important covariates.

resultsAmong 119,937 individuals with Lung cancer, 52.1% were in California (62,521), while 47.8% were in Texas (57,416). The pre-ACA period included 60,010 individuals (53.1% in California and 46.9% in Texas), and 59,927 patients were in the post-ACA period (51.2% in California and 48.8% in Texas). Overall, Medicaid expansion was associated with a 1.12-point (-1.12, 95% CI -1.46 to -0.77) reduction in the hazard of cancer-specific mortality. The policy was also associated with a 0.81point reduction in the hazard of overall mortality (-0.81, 95% CI -1.06 to -0.57).

conclusionMedicaid expansion was associated with a significant improvement in lung cancer outcomes among individuals with lung cancer in California, which implemented the policy in 2014, compared to Texas, which has not yet implemented the policy.

Indexed as

CaliforniaCancer-specific mortalityDifference in differencesLung cancer survivalMedicaid expansionOverall mortalityTexas

Identifiers

PMID40950489
PMCPMC12425007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.